<DOC>
	<DOCNO>NCT01310296</DOCNO>
	<brief_summary>The purpose study determine mass balance absolute bioavailability single oral dose 14C-labeled lofexidine compare single intravenous dose lofexidine .</brief_summary>
	<brief_title>Lofexidine ADME &amp; Mass Balance Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Lofexidine</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<criteria>Subject must male nonpregnant , nonbreastfeeding female . Subject must 18 50 year age ( inclusive ) . Subject 's Body Mass Index ( BMI ) must 18 30 kg/m2 ( inclusive ) , subject must weigh minimum 50 kg ( 110 lb ) . Female subject must agree use one follow form birth control screen 14 day completion study : Vasectomized partner ( least 6 month prior dose ) Postmenopausal ( least 2 year prior dose ) Surgically sterile ( bilateral tubal ligation , hysterectomy , bilateral oophorectomy ) least 6 month prior dose Double barrier ( diaphragm spermicide ; condom spermicide ) IUD ( intrauterine device ) Abstinence ( must agree use double barrier method become sexually active study ) Implanted intrauterine hormonal contraceptive use least 6 consecutive month prior study dose throughout study duration Oral , patch , injected contraceptive vaginal hormonal device ( i.e . NuvaRing® ) use least 3 consecutive month prior study dose throughout study duration . Subject must voluntarily consent participate study provide write informed consent prior start study specific procedure . Subject willing able remain study unit entire duration confinement period . Subject 's vital sign must within follow range include : Vital sign measure sit 3 minute rest ; heart rate : 5090 bpm ; systolic BP : 100140 mmHg ; diastolic BP : 5090 mmHg , oral temperature within normal range 35.637.7° C. Outofrange vital sign may repeat . Predose vital sign assess Principal Investigator designee ( e.g. , medically qualified subinvestigator ) prior study drug administration . The Principal Investigator designee verify eligibility subject outofrange vital sign document approval prior dose . For study period subject assign receive Treatment A ( lofexidine oral solution contain 14Clofexidine ) , subject must : Willing eat entire meal snack provide confinement research facility ; understand diet include food high fiber content possibly prune juice . Willing remain clinical research center minimum 7 consecutive day predose , dose , postdose evaluation period . Subjects must willing stay additional 24 48 hour necessary . Willing collect urine fecal sample duration study period require . History presence clinically significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , oncologic , psychiatric disease condition , opinion Investigator , would jeopardize safety subject validity study result . Has clinically significant abnormal find physical exam , medical history , ECG , clinical laboratory result screen . Hstory syncopal episode seizure . Presence acute disease state ( eg , nausea , vomit , fever , diarrhea ) within 7 day prior schedule dose administration . History presence allergic adverse response lofexidine relate drug . Has significantly abnormal diet 4 week precede first dose study medication . Has donate blood plasma within 30 day prior first dose study medication . Has participate radiolabeled clinical trial within last 12 month prior first dose study medication . Has participate another clinical trial ( randomized subject ) within 30 day prior first dose study medication . Has use overthecounter ( OTC ) medication , include nutritional supplement , within 7 day prior first dose study medication . Has use prescription medication , except hormonal contraceptive hormonal replacement therapy , within 14 day prior first dose study medication . Subjects discontinue use implant , intrauterine , inject hormonal contraceptive must use 6 month prior study start . Subjects discontinue use oral , patch , vaginal hormonal contraceptive must use 1 month prior study start . Has treat know drug moderate strong inhibitors/inducers CYP enzymes barbiturate , phenothiazine , cimetidine , carbamazepine , etc. , within 30 day prior first dose study medication Investigator 's judgment may impact subject safety validity study result . Has smoke use tobacco product within 60 day prior first dose study medication . Has prior history substance abuse treatment ( include alcohol ) within past 2 year . Is female positive pregnancy test result . Has positive urine screen drug abuse ( amphetamine , barbiturate , benzodiazepine , cocaine , cannabinoids , opiate ) . Has positive test , treat hepatitis B , hepatitis C , Human Immunodeficiency Virus ( HIV ) . Has orthostatic hypotension screening define drop systolic blood pressure ≥ 20 mmHg fall diastolic blood pressure ≥ 10 mmHg follow 2 minute stand . Outofrange vital sign may repeat . Predose vital sign assess Principal Investigator designee ( e.g. , medically qualified subinvestigator ) prior study drug administration . The Principal Investigator designee verify eligibility subject outofrange vital sign document approval prior dose . Subjects QTcB great 450 msec ( male ) great 470 msec ( female ) , screen obtain 5 minute rest supine position use ECG machine algorithm . Has irregular bowel habit . ( `` Irregular '' define purpose study NOT bowel movement least every 2 day . ) Has expose radiation , include dental medical imaging x ray tomography , 6 month prior dose administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Normal Healthy Volunteers</keyword>
	<keyword>Mass Balance</keyword>
	<keyword>ADME</keyword>
	<keyword>Absolute Bioavailability</keyword>
</DOC>